What To Look Forward To At Ash | Ola Landgren, Md, Phd | Ash 2022

What to Look Forward to at ASH | Ola Landgren, MD, PhD | ASH 2022

HealthTree Foundation for Multiple Myeloma

ASH 2022: What to look forward to in the field of multiple myeloma

VJHemOnc – Video Journal of Hematology & HemOnc

What to look forward to in lymphoma at ASH 2022

VJHemOnc – Video Journal of Hematology & HemOnc

Dr Landgren on the Management of Newly Diagnosed Multiple Myeloma Treatment

Dr. C. Ola Landgren - ASH 2024

Sylvester Comprehensive Cancer Center

New Developments at ASH | Rafat Abonour, MD | ASH 2022

HealthTree Foundation for Multiple Myeloma

Dr. Landgren on the Use of Triplets Versus Quadruplets in Multiple Myeloma

The importance of MRD in multiple myeloma in guiding treatment decisions & access to therapies

VJHemOnc – Video Journal of Hematology & HemOnc

ASH 2019: 80% of patients MRD negative! (newly diagnosed) — Dara + KRd Results | Dr. Ola Landgren

HealthTree Foundation for Multiple Myeloma

Advancements in Myeloma Precision Medicine | Ola Landgren, MD, PhD

HealthTree Foundation for Multiple Myeloma

MCL: what to look forward to at ASH 2020

VJHemOnc – Video Journal of Hematology & HemOnc

Novel AI model for personalized risk stratification & treatment in newly diagnosed multiple myeloma

VJHemOnc – Video Journal of Hematology & HemOnc

Dr. Landgren on the Treatment of High-Risk Smoldering Myeloma

Targeted Oncology

Dr. Ola Landgren on Carfilzomib and Pomalidomide in Myeloma

Prof. Ola Landgren | ASH 2017 | Key controversies in Myeloma

Multiple Myeloma Hub

AML: what to look forward to at ASH 2020

VJHemOnc – Video Journal of Hematology & HemOnc

C. Ola Landgren, MD, PhD, relays his thoughts on the most exciting news at ASH for MM patients

Dr. Landgren on the Standard of Care in Multiple Myeloma

Dr. Ola Landgren on Combinations in Newly Diagnosed Myeloma